A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer



Status:Active, not recruiting
Conditions:Colorectal Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/9/2017
Start Date:June 2016
End Date:October 2019

Use our guide to learn which trials are right for you!

A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer

This study is a randomized, double-blind, post-chemotherapy, adjuvant phase III clinical
trial. The primary aim of this study is to determine the value of regorafenib in improving
disease-free survival (DFS). Patients with Stage III (IIIB or IIIC) colon cancer as defined
by the 7th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual are
randomized 1:1 to placebo or the experimental agent regorafenib following completion of at
least four months of standard adjuvant therapy (e.g., 5-fluorouracil, leucovorin, oxaliplatin
(FOLFOX) , capecitabine, oxaliplatin (CapeOx), and other).

The primary aim of this study is to determine the value of regorafenib in improving DFS. The
secondary aims are to evaluate the dose tolerance and long term toxicity of two years of
regorafenib following standard adjuvant therapy, and to evaluate the effect of the use of
regorafenib in overall survival (OS).

Eligible patients in this double-blind study will be randomized to take either regorafenib
120 mg or placebo orally, once daily for 21 consecutive days of a 28 day cycle for 26 cycles
(2 years).

Accrual for this study will be approximately 1118 randomized patients. These 1118 patients
will provide approximately 313 DFS events at the time of primary analysis. An initial
futility analysis will be performed when 312 patients have been on study at least 3 months.
The decision to continue the trial will be determined by success of both early stopping
endpoints defined as follows:

- The toxicity profile of regorafenib compared to placebo is acceptable.

- The regorafenib regimen is tolerable for prolonged administration.

An estimated compliance rate of 60% at 6 months for regorafenib will be required for
continuation of the study.

If toxicity is acceptable and compliance with regorafenib is at least 60% nominally, then
accrual will continue.

The second futility analysis will be conducted when approximately 67 DFS events are observed.
Trial conduct and accrual will continue unless the primary endpoint (DFS) trends too far in
the opposite direction (hazard ratio greater than or equal to 1.1).

Toxicity will be graded according to the National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.0.

NSABP C-13 will include a Behavioral and Health Outcomes correlative science component. A
C-13 Quality of Life (QOL) questionnaire will be administered at baseline (after consent and
prior to randomization) and at 3 months, 6 months, 12 months, 18 months, 24 months, and 30
months.

Submission of blood samples for C-13 correlative science studies will be a study requirement
for all patients. Submissions will also include archived primary tumor tissue from the
resected colon primary. Blood samples for pharmacokinetics (PK) will be collected on Day 15
of Cycle 1 and Day 15 of Cycle 2, with additional blood samples for biomarkers collected at
various time points for future analysis.

Inclusion Criteria:

- The Eastern Cooperative Oncology Group (ECOG) performance status must be 0-1

- There must be histologic confirmation of high risk, adenocarcinoma of the colon
defined as AJCC 7th Edition Stage IIIB or IIIC.

- The patient must have had an en bloc complete gross resection of tumor (curative
resection) by open laparotomy or laparoscopically-assisted colectomy. The distal
extent of the tumor must have been greater than or equal to 12 cm from the anal verge.
(Patients who have had a two-stage surgical procedure to first provide a decompression
colostomy and then in a later procedure to have a surgical resection are eligible.)

- Imaging (positron emission tomography/computed tomography (PET/CT) scan, CT scan, or
magnetic resonance imaging (MRI)) of chest, abdomen, and pelvis must be performed
within 90 days prior to randomization and must demonstrate no evidence of metastatic
disease. If findings noted in imaging study reports are equivocal, the determination
of whether or not the findings represent metastatic disease will be at the
investigator's discretion.

- The patient must be able to swallow oral medication.

- The patient must have completed at least 4 months of adjuvant chemotherapy (i.e.,
FOLFOX, CapeOx, or other, such as 5-fluorouracil, leucovorin, oxaliplatin (FLOX),
5-fluorouracil/leucovorin (5FU/LV), capecitabine).

- The interval between completion of standard adjuvant chemotherapy and randomization
must be less than or equal to 60 days.

- Blood counts performed within 28 days prior to randomization must meet the following
criteria:

- Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;

- platelet count must be greater than or equal to 100,000/mm3; and

- hemoglobin must be greater than or equal to 9 g/dL.

- The following criteria for evidence of adequate hepatic function performed within 4
weeks prior to randomization must be met:

- total bilirubin must be less than or equal to 1.5 x upper limit of normal (ULN);
and

- alkaline phosphatase must be less than or equal to 2 x ULN; and

- Asparate aminotransferase (AST) and alanine aminotransferase (ALT) must be less
than or equal to 2 x ULN for the lab. (Note: If AST and/or ALT greater than ULN,
serologic testing for Hepatitis B and C must be performed and results must be
negative.)

- Lipase performed within 28 days of randomization must be less than or equal to 1.5 x
ULN for the lab.

- Serum creatinine performed within 28 days of randomization must be less than or equal
to 1.5 x ULN for the lab.

- Urinalysis dipstick for urinary protein performed within 28 days prior to
randomization must be 0-1+ protein. If urine dipstick result is greater than or equal
to 2+ protein, a 24-hour urine protein must be less than 1.0 g/24 hours.

- Glomerular filtration rate (GFR) must be greater than or equal to 30 mL/min/1.73 m2
according to the Modified Diet in Renal Disease (MDRD) abbreviated formula.

- International normalized ratio of prothrombin time must be less than or equal to 1.5
times the ULN. Patients who are therapeutically treated with an agent such as warfarin
or heparin will be allowed to participate if no underlying abnormality in coagulation
parameters exists per medical history.

- Patients (male or female) of reproductive potential must agree to use an effective
method of contraception (as discussed with treating physician) from the time consent
is signed, during study therapy, and for at least 90 days after the last dose of study
therapy.

- Patients with prior malignancies are eligible if they have been disease-free for at
least 5 years and are deemed by their physician to be at low risk for recurrence.
Patients with squamous or basal cell carcinoma of the skin, melanoma in situ,
carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have
been effectively treated are eligible, even if these conditions were diagnosed within
5 years of randomization.

Exclusion Criteria:

- Isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.

- Colon cancer other than adenocarcinoma (e.g., sarcoma, lymphoma, carcinoid).

- Prior history of invasive adenocarcinoma of colon or rectum.

- Patients with active autoimmune disease. (Patients with endocrine autoimmune diseases
requiring replacement therapy alone are allowed.)

- Gastroduodenal ulcer(s) determined by endoscopy to be active.

- Any malabsorption condition.

- Known history of human immunodeficiency virus (HIV) infection or chronic or active
hepatitis B or hepatitis C requiring treatment with antiviral therapy.

- Any concomitant systemic therapy or radiation therapy initiated for this malignancy.

- Active infection, or chronic infection requiring chronic suppressive antibiotics.

- Persistent CTCAE v4.0 greater than or equal to grade 2 diarrhea regardless of
etiology.

- Know history of allografts (including corneal transplant).

- Chronic daily treatment with corticosteroids with a dose of greater than or equal to
10 mg/day methylprednisolone equivalent (excluding inhaled steroids), or any other
immunosuppressive drugs.

- Any significant bleeding (greater than or equal to grade 3, hemorrhage) that is not
related to the primary colon tumor within 6 months before randomization.

- Any of the following cardiac conditions:

- documented New York Heart Association (NYHA) Class III or IV congestive heart
failure;

- myocardial infarction within 6 months prior to randomization;

- unstable angina (angina symptoms at rest) within less than or equal to 3 months
prior to randomization; and

- clinically significant symptomatic arrhythmia despite anti-arrhythmic therapy.

- Uncontrolled blood pressure (systolic pressure greater than 150 mmHg or diastolic
pressure greater than 90 mmHg on repeated measurements).

- Symptomatic brain or meningeal tumors.

- Patients with seizure disorder requiring medication.

- Presence of non-healing wound, non-healing ulcer, or bone fracture.

- Symptomatic interstitial lung disease or definitive evidence of interstitial lung
disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at
rest requiring current continuous oxygen.

- Arterial or venous thrombotic or embolic events such as cerebral vascular accident
(including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
within 6 months before randomization (except for adequately treated catheter-related
venous thrombosis occurring within 6 months before randomization).

- Symptomatic peripheral ischemia.

- Psychiatric or addictive disorders or other conditions or unresolved toxicities of
prior therapy greater than grade 2 that, in the opinion of the investigator, would
preclude the patient from meeting the study requirements, or interfere with
interpretation of study results.

- Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be
performed within 14 days prior to randomization according to institutional standards
for women of childbearing potential.)

- Major surgery (including ostomy reversal), open biopsy or significant trauma injury,
within 28 days prior to randomization.

- Anticipation of need for major surgical procedures during the course of study.

- Known hypersensitivity to study drug, study drug classes or excipients of the
formulation.

- Use of any vascular endothelial growth factor (VEGF) targeted therapy or previous use
of regorafenib.

- Patients taking strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) who
cannot interrupt therapy from the time the C-13 consent is signed through 30 days
after the last dose of study therapy.

- Patients taking herbal remedies (e.g., St. John's Wort [Hypericum perforatum]) who
cannot interrupt therapy from the time the C-13 consent is signed through 30 days
after the last dose of study therapy.

- Use of immune modulators and/or any immunosuppressive drugs.

- Use of any investigational agent within 28 days of randomization.

- Patients receiving erythropoiesis-stimulating agents or other hematopoietic growth
factors.
We found this trial at
51
sites
Santa Rosa, California 95403
?
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
?
mi
from
Abington, PA
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
Phone: 412-339-5333
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
?
mi
from
Camden, NJ
Click here to add this to my saved trials
Cary, North Carolina 27511
?
mi
from
Cary, NC
Click here to add this to my saved trials
?
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Davenport, Iowa 52804
?
mi
from
Davenport, IA
Click here to add this to my saved trials
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Denver, Colorado 80224
?
mi
from
Denver, CO
Click here to add this to my saved trials
555 East Cheves Street
Florence, South Carolina 29502
?
mi
from
Florence, SC
Click here to add this to my saved trials
Gastonia, North Carolina 28054
?
mi
from
Gastonia, NC
Click here to add this to my saved trials
?
mi
from
Green Bay, WI
Click here to add this to my saved trials
Hendersonville, North Carolina 28791
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Phone: 800-531-1535
?
mi
from
Hershey, PA
Click here to add this to my saved trials
?
mi
from
Kingsport, TN
Click here to add this to my saved trials
1915 White Ave.
Knoxville, Tennessee 37916
(865) 541-1678
Thompson Cancer Survival Center The Thompson Cancer Survival Center Downtown facility has pioneered many advances...
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lansing, Michigan 48910
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Las Vegas, Nevada 89106
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Long Branch, New Jersey
?
mi
from
Long Branch, NJ
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Miami Beach, Florida 33140
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Morgantown, West Virginia 26506
(304) 293-0111
West Virginia University West Virginia University, founded in 1867, has a long and rich history...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Naperville, Illinois 60540
?
mi
from
Naperville, IL
Click here to add this to my saved trials
New Haven, Connecticut 6520
(203) 432-4771
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
1430 Tulane Ave Suite SL32
New Orleans, Louisiana 70112
(504) 588-5912
Tulane University Health Sciences Center One of the nation's most recognized centers for medical education,...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
201 Lyons Ave
Newark, New Jersey 07112
(973) 926-7000
Newark Beth Israel Medical Center Newark Beth Israel Medical Center, a regional care, teaching hospital...
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Omaha, Nebraska 68106
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
111 S 11th St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pinehurst, North Carolina 28374
?
mi
from
Pinehurst, NC
Click here to add this to my saved trials
320 E North Ave
Pittsburgh, Pennsylvania 15212
(412) 359-3131
Allegheny General Hospital At Allegheny General Hospital, our physicians and healthcare staff have earned an...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsfield, Massachusetts 01201
?
mi
from
Pittsfield, MA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Saint Louis Park, Minnesota 55416
?
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
4700 Waters Ave
Savannah, Georgia 31404
(912) 350-8000
Memorial Health University Medical Center Memorial University Medical Center (MUMC) is a nonprofit, 622-bed tertiary...
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Sayre, Pennsylvania 18840
?
mi
from
Sayre, PA
Click here to add this to my saved trials
Scarborough, Maine 04074
Phone: 412-339-5333
?
mi
from
Scarborough, ME
Click here to add this to my saved trials
Scranton, Pennsylvania 18510
?
mi
from
Scranton, PA
Click here to add this to my saved trials
615 N Michigan Street
South Bend, Indiana 46601
(574) 647-7370
Northern Indiana Cancer Research Consortium The Northern Indiana Cancer Research Consortium (NICRC) is comprised of...
?
mi
from
South Bend, IN
Click here to add this to my saved trials
Toledo, Ohio 43623
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Toms River, New Jersey 08755
?
mi
from
Toms River, NJ
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Vallejo, California 94589
Phone: 707-651-1000
?
mi
from
Vallejo, CA
Click here to add this to my saved trials
Waterloo, Iowa 50702
?
mi
from
Waterloo, IA
Click here to add this to my saved trials
West Reading, Pennsylvania 19611
?
mi
from
West Reading, PA
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials